At Pharmapack Europe in Paris, Sanner and Amiko presented their cooperation for the development of smart add-on solutions for inhaled drug delivery systems. Sanner Ventures, parent company of Sanner GmbH and corporate venture capital office specializing in new technologies in the area of health and well-being, supports Amiko Digital Health Limited with a strategic investment. The funds will be used to expand Amiko’s flagship product, the Respiro platform, an innovative respiratory disease management tool.
Heading towards true medication adherence
On the operational side, Sanner GmbH, headquartered in Bensheim, Germany, will work closely with Amiko to incorporate the start-up’s patented sensor technology into custom add-on or integrated device solutions for pharmaceutical clients. “Sanner has profound experience in moisture protection solutions and custom-made primary plastic packaging, as well as in design for manufacturing and industrialization of drug delivery systems,” says Dirk Mähr, Managing Director of Sanner GmbH. “Together with Amiko’s digital Respiro Platform and unique sensor technology, we will transform our synergies into smart solutions for true medication adherence in respiratory care.”
Amiko, winner of the 1st prize at the IBM Watson AI XPRIZE annual Milestone Award 2017, is upgrading respiratory care with sensors and AI technologies. Amiko’s Respiro platform, which has recently received the CE mark for use with certain inhaler systems, enables real-time monitoring of medication use and patient health. The patented Respiro Sense sensors, which are attached to dry powder inhalers, not only track device usage. They also facilitate true medication adherence by ensuring the medication is administered in the right way following the right technique. “Our digital health tools assist healthcare professionals and empower patients to achieve better respiratory treatment results,” says Duilio Macchi, CEO and Co-Founder of Amiko. “Together with Sanner we will advance our mission to upgrade respiratory care, improve health outcomes and reduce the costs of care for pulmonary diseases via AI-powered mobile health solutions.”